Key Developments: RTI Surgical Inc (RTIX.OQ)

RTIX.OQ on NASDAQ Stock Exchange Global Select Market

4.02USD
11:17am EDT
Price Change (% chg)

$-0.05 (-1.23%)
Prev Close
$4.07
Open
$4.09
Day's High
$4.09
Day's Low
$4.00
Volume
15,838
Avg. Vol
72,208
52-wk High
$5.11
52-wk Low
$3.54

Search Stocks

Latest Key Developments (Source: Significant Developments)

RTI Biologics Inc Completes Acquisition Of Pioneer Surgical Technology; Announces Name Change
Tuesday, 16 Jul 2013 04:00pm EDT 

RTI Biologics Inc announced that it has completed the acquisition of Pioneer Surgical Technology (Pioneer). RTI previously announced plans to acquire all of the outstanding stock of Pioneer for $130 million in cash on June 12, 2013. The transaction was funded through a combination of cash on hand, a 5-year $80 million senior secured credit facility, which includes a $60 million term loan and a $20 million revolving credit facility, from TD Bank, N.A., TD Securities USA LLC, and Regions Bank, and a $50 million concurrent private placement of convertible preferred equity from Water Street Healthcare Partners (Water Street), a strategic private equity firm focused exclusively on the health care industry. Effective immediately, the new name of the Company is RTI Surgical Inc. The Company's worldwide headquarters will remain in Alachua, Fla. and the stock will continue to trade on the Nasdaq Global Market under the symbol RTIX.  Full Article

RTI Biologics Inc Announces Agreement To Acquire Pioneer Surgical Technology
Wednesday, 12 Jun 2013 07:00am EDT 

RTI Biologics Inc announced that its intent to acquire privately held Pioneer Surgical Technology, headquartered in Marquette, Mich. Pioneer is a medical technology company that manufactures and distributes metal and synthetic products in the orthopedics, biologics, spine, trauma and cardiothoracic markets. Under the terms of the merger agreement, RTI will pay $130 million in cash to acquire all the outstanding stock of Pioneer. The transaction will be funded through a combination of cash on hand, a new credit facility and a concurrent private placement of convertible preferred equity from Water Street Healthcare Partners. Additionally, RTI has agreed to a $50 million private placement of convertible preferred equity with Water Street, a healthcare-focused private equity firm with operating experience and industry knowledge.  Full Article

RTI Biologics Inc Raises Low End Of Prior FY 2013 Revenue Guidance To A Range Above Analysts' Estimates; Reaffirms FY 2013 EPS Guidance; Issues Q2 2013 Guidance In Line With Analysts' Estimates
Thursday, 25 Apr 2013 08:09am EDT 

RTI Biologics Inc announced that for fiscal 2013, it expects revenues to be between $179-$182 million, net income per fully diluted share to be in the range of $0.17 to $0.19. For the second quarter of 2013, the Company expects revenues to be between $42 million and $43 million, and net income per fully diluted share to be approximately $0.03. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $178 million and EPS of $0.17 for fiscal 2013; revenue of $43 million and EPS of $0.03 for the second quarter of 2013.  Full Article

RTI Biologics Inc Announces Positive Clinical Results For BioCleanse-Processed BTB Allografts Used In ACL Reconstruction
Wednesday, 20 Mar 2013 08:30am EDT 

RTI Biologics Inc announced the results of a recent randomized prospective clinical study of BioCleanse-processed bone-patellar tendon-bone (BTB) allografts used in anterior cruciate ligament (ACL) reconstruction surgery. The study was published in the peer reviewed journal, Knee Surgery, Sports Traumatology, Arthroscopy, in December 2012. The article compares the clinical outcomes of BTB allografts processed using RTI`s patented BioCleanse Tissue Sterilization Process with a control group consisting of aseptically-processed allografts from the three U.S. tissue banks that provide this type of allograft. According to the American Association of Tissue Banks` 13th edition of Standards for Tissue Banking, aseptic processing refers to the processing of tissue using methods to prevent, restrict or minimize contamination with microorganisms from the environment, processing personnel, and/or equipment. A total of 67 patients undergoing ACL reconstruction at six independent investigation sites were evaluated at six, 12 and 24 months. After randomization, 24 patients received aseptic BTB allografts and 43 patients received BioCleanse-sterilized allografts. According to Millennium Research Group`s U.S. Markets for Orthopedic Soft Tissue Solutions 2011" report, more than 457,400 ACL reconstructions are performed annually in the U.S., with 21% of those using allograft implants.  Full Article

RTI Biologics Inc Receives 510(k) Clearance For Porcine Dermis Implant
Wednesday, 13 Mar 2013 07:45am EDT 

RTI Biologics Inc announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for porcine dermis implant. The implant is intended for use in soft tissue repair procedures such as hernia repair. Stored hydrated and ready-to-use, the porcine dermis implant is comprised of non-crosslinked porcine dermis, designed to act as a scaffold that allows for neovascularization and reincorporation with the patient`s own tissue. The implants will be made available in various shapes and sizes. The implants will be processed at RTI`s facility in Neunkirchen, Germany for commercial distribution in the U.S. later this year. The facility has been validated for processing and has begun production of the implants.  Full Article

RTI Biologics Inc Issues FY, Q1 2013 Guidance Below Analysts' Estimates
Thursday, 7 Feb 2013 08:00am EST 

RTI Biologics Inc announced that for fiscal 2013, it expects revenues to be between $178-$182 million, net income per fully diluted share to be in the range of $0.17 to $0.19. For the first quarter of 2013, the Company expects revenues to be between $38 million and $39 million, and net income per fully diluted share to be approximately $0.02. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $189 million and EPS of $0.22 for fiscal 2013; revenue of $46 million and EPS of $0.05 for the first quarter of 2013.  Full Article

RTI Biologics Inc Narrows FY 2012 Revenue Outlook To A Range In Line With Analysts' Estimates; Revises FY 2012 EPS Outlook To A Range Below Analysts' Estimates; Issues Q4 2012 Outlook Below Estimates
Thursday, 25 Oct 2012 08:00am EDT 

RTI Biologics Inc announced that for fiscal 2012, it expects revenue to be between $178-$179 million and net income per fully diluted share for 2012 to be approximately $0.15. Excluding a pre-tax litigation settlement charge of $2.35 million taken in the second quarter of 2012, or $0.03 per fully diluted share, the Company expects full year net income per fully diluted share for 2012 to be approximately $0.18, based on 56.1 million shares outstanding. For the fourth quarter of 2012, the Company expects revenues to be between $44-$45 million, and net income per fully diluted share to be $0.04. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $179 million and EPS of $0.18 for fiscal 2012; revenue of $46 million and EPS of $0.05 for the fourth quarter of 2012.  Full Article

RTI Biologics Inc Raises FY 2012 Guidance; Issues Q3 2012 Guidance; Revenue Guidance Above Analysts' Estimates
Tuesday, 31 Jul 2012 07:00am EDT 

RTI Biologics Inc announced that as a result of first half 2012 results that exceeded expectations and better visibility into second half 2012 trends, the Company has raised fiscal 2012 revenues guidance and now expects revenues to be between $177 million to $179 million, as compared to prior guidance of $176 million to $178 million. As a result of the litigation settlement charge of $0.03 per fully diluted share taken in the second quarter 2012, fiscal 2012 net income per fully diluted share (EPS) is now expected to be in the range of $0.14 to $0.15, as compared to prior guidance of $0.16 to $0.17 per fully diluted share. For the third quarter of 2012, the Company expects revenues to be between $44 million and $45 million and net income per fully diluted share to be approximately $0.04. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $177 million and EPS of $0.17 for fiscal 2012; and revenue of $43 million and EPS of $0.04 for the third quarter of 2012.  Full Article

RTI Biologics Inc Raises FY 2012 Revenue Guidance; Raises Low End Of Prior FY 2012 EPS Guidance To A Range In Line With Analysts' Estimates; Issues Q2 2012 Guidance In Line With Analysts' Estimates
Thursday, 26 Apr 2012 08:00am EDT 

RTI Biologics Inc announced that as a result of better than expected results in the first quarter, the Company is raising its fiscal 2012 revenue guidance. The Company now expects revenues for fiscal 2012 to be between $176 million and $178 million, as compared to prior guidance of between $174 million and $176 million. Fiscal 2012 net income is expected to be between $0.16 and $0.17 per fully diluted share (EPS), as compared to its prior guidance of between $0.15 and $0.17 per fully diluted share. For the second quarter of 2012, the Company expects revenues to be between $43 million and $44 million, and net income per fully diluted share to be approximately $0.04. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $176 million and EPS of $0.16 for fiscal 2012; and revenue of $44 million and EPS of $0.04 for the second quarter of 2012.  Full Article

RTI Biologics Inc Issues Q1 2012 Guidance In Line With Analysts' Estimates; Issues FY 2012 Guidance; EPS Guidance Below Analysts' Estimates
Tuesday, 31 Jan 2012 08:00am EST 

RTI Biologics Inc announced that for first quarter of 2012, it expects revenues to be between $41 million and $42 million, and net income per fully diluted share to be approximately $0.03. For fiscal 2012, it expects revenue to be in the range of $174 million and $176 million. Net income per fully diluted share is expected to be in the range of $0.15 to $0.17, based on 55.8 million fully diluted shares outstanding. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $42 million and EPS of $0.04 for first quarter of 2012; revenue of $176 million and EPS of $0.18 for fiscal 2012.  Full Article

Search Stocks